Birchview Capital’s Cullinan Oncology CGEM Stock Holding History

Birchview Capital’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$364K	Hold	20,000	–	–	0.17%	57
2026 Q1	$284K	Hold	20,000	–	–	0.16%	64
2025 Q4	$207K	Hold	20,000	–	–	0.12%	64
2025 Q3	$119K	Hold	20,000	–	–	0.09%	66
2025 Q2	$151K	Hold	20,000	–	–	0.15%	63
2025 Q1	$151K	Hold	20,000	–	–	0.13%	57
2024 Q4	$244K	Hold	20,000	–	–	0.2%	53
2024 Q3	$335K	Hold	20,000	–	–	0.29%	41
2024 Q2	$349K	Sell	20,000 -5,114	-20%	-$109K	0.32%	40
2024 Q1	$428K	Hold	25,114	–	–	0.35%	38
2023 Q4	$256K	Hold	25,114	–	–	0.2%	45
2023 Q3	$227K	Hold	25,114	–	–	0.19%	44
2023 Q2	$270K	Hold	25,114	–	–	0.2%	48
2023 Q1	$257K	Hold	25,114	–	–	0.2%	46
2022 Q4	$265K	Hold	25,114	–	–	0.19%	46
2022 Q3	$322K	Sell	25,114 -20,000	-44%	-$269K	0.23%	46
2022 Q2	$578K	Hold	45,114	–	–	0.42%	35
2022 Q1	$472K	Hold	45,114	–	–	0.34%	42
2021 Q4	$696K	Hold	45,114	–	–	0.45%	36
2021 Q3	$1.02M	Hold	45,114	–	–	0.69%	28
2021 Q2	$1.16M	Sell	45,114 -15,000	-25%	-$461K	0.7%	25
2021 Q1	$2.5M	Buy	+60,114	New	+$2.44M	1.49%	12

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Birchview Capital's CGEM Position: Q2 2026 in Review

Birchview Capital held its Cullinan Oncology (CGEM) position steady in Q2 2026 at 20,000 shares worth $364K. The position accounts for 0.17% of the portfolio, ranked #57.

Birchview Capital first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.5M in Q1 2021. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

Birchview Capital held 20,000 shares of Cullinan Oncology worth $364K as of Q2 2026.
Birchview Capital left its Cullinan Oncology share count unchanged in Q2 2026.
Cullinan Oncology made up 0.17% of Birchview Capital's portfolio in Q2 2026, its #57 holding.
Birchview Capital first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
Birchview Capital's Cullinan Oncology position peaked at $2.5M in Q1 2021.
184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.